Immunocore Holdings plc (NASDAQ:IMCR) Kneel Downs on Presents Promising Initial Phase 1 Data

Immunocore Holdings plc (NASDAQ:IMCR) kneel downs to $44.75 per share that compromise more than 22% in last trading session after the firm revealed initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types.

 

The preliminary results of IMC-ongoing F106C’s Phase 1 dosage escalation study will be presented today at 4:40 PM CEST/10:40 AM EDT in the Investigational Immunotherapy Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress. The presentation is available in the ‘News & Events’ section of the Company’s website’s Investor Relations section.

Chief Executive Officer of Immunocore, Bahija Jallal stated that the long-term results in severely pre-treated patients demonstrate that their PRAME-targeted bispecific medication, IMC-F106C, can help patients with a variety of cancer types. Based on these positive findings, they have begun expansion arms in a variety of tumor types to further evaluate effectiveness.

Chief of the firm Dr. Omid Hamid said: “ImmTAC therapies are designed to provide potent and target-specific T-cell response, overcoming resistance in immune excluded tumors. Through redirection and activation of non-tumor-specific T cells, as shown in this trial with IMC-F106C, we can influence a diverse range of tumors leading to durable response. This trial shows tolerability and activity in a wide range of tumors, including checkpoint inhibitor pre-treated patients. I look forward to upcoming cohorts in combination with checkpoint inhibitors and chemotherapy.”

Patient recruitment in four expansion arms in cutaneous melanoma, ovarian, non-small cell lung cancer (NSCLC), and endometrial malignancies has begun. The IMC-F106C-101 study is adaptive and includes a Phase 2 expansion option, allowing for roughly 100 patients per tumor type to be treated in the Phase 1 and 2 expansion arms. Dose escalation in other solid tumors is ongoing, and preparations for combination arms with standard-of-care are in the works.

Leave a Reply

Your email address will not be published.